Budipine in Parkinson's tremor

  title={Budipine in Parkinson's tremor},
  author={Heinz Reichmann},
  journal={Journal of the Neurological Sciences},
  • H. Reichmann
  • Published 25 October 2006
  • Medicine, Psychology
  • Journal of the Neurological Sciences
Tremor revisited: treatment of PD tremor.
Paradoxical aspects of parkinsonian tremor
  • P. Fishman
  • Medicine, Psychology
    Movement disorders : official journal of the Movement Disorder Society
  • 2008
Although the thalamus has the greatest body of evidence supporting its role as an effective target for surgical treatment of tremor, recent studies suggest that the subthalamic nucleus may be a reasonable alternative target for patients with Parkinson's disease and severe tremor as the predominant symptom.
The differential diagnosis and treatment of tremor.
Most patients with tremor can be given a precise diagnosis and offered specific treatment, and it is important for the physician to inform the patient about the expected course of tremor over time, its possible genetic causes, and the various available treatments.
Medications used to treat tremors
Resting tremor in Parkinson disease: a negative predictor of levodopa-induced dyskinesia.
Resting tremor as an initial manifestation of PD predicts lower probability of developing levodopa-induced dyskinesia underlevodopa treatment, independent of other predictors of LID.
Other drugs acting on nervous system associated with QT-interval prolongation.
Knowing the pharmacological properties of antidepressants and antipsychotic drugs is of vital importance to avoid exposing particularly vulnerable individuals as those with congenital long QT syndrome, and even the general public to unnecessary risk of potentially fatal arrhythmias.
Treatment strategies in early and advanced Parkinson disease.
Medikamentöse Therapie der motorischen Symptome beim Morbus Parkinson
In order that the advantages of the individual medications can be exploited and undesired effects and interactions can be avoided, one must come to terms with the complex data and the pharmacology of the medication.
Virtual reality and hand tracking system as a medical tool to evaluate patients with parkinson's
A virtual reality scene to engage the patient to feel in an activity that can be found in daily life, and the Leap Motion controller tracking is used to evaluate and classify the tremor in the hands.


Budipine Treatment of Neuroleptic-Induced Parkinsonism
The development of drugs with better efficacy than that of anticholinergics or with an alternative approach is of substantial clinical importance, especially for chronic schizophrenics under long-term neuroleptic treatment.
[Monotherapy of Parkinson's disease with budipine. A double blind comparison with amantadine].
Budipine showed a significantly better effect on the main symptom tremor after 12 weeks compared to amantadine, and caused a clinically relevant and statistically significant improvement of Parkinsonian symptoms according to the Webster-Rating-Scale (WRS) as compared to pretreatment values.
Budipine provides additional benefit in patients with Parkinson disease receiving a stable optimum dopaminergic drug regimen.
The additional application of budipine provides further therapeutic benefit in subjects with Parkinson disease receiving a stable, prior, optimum-titrated dopaminergic drug regimen because of the hypothetical positive impact of Budipine on altered nondopaminergic neurotransmission in patients with Parkinson Disease.
Adjuvant treatment of Parkinson's disease with budipine: a double-blind trial versus placebo
Owing to its long half-life (31 h) with little plasma level fluctuations, budipine appears to be an effective agent in the treatment of Parkinson's disease.
Biochemical and Pharmacologic Aspects of the Mechanism of Action of Budipine
In reserpine-induced Parkinson syndrome, budipine brings about an increase in the levels of biogenic amines in the nucleus caudatus and also in the whole brain, and it is suggested that the increase is due to a reuptake inhibition.
Antiparkinsonian actions of glutamate antagonists — alone and with L-DOPA: A review of evidence and suggestions for possible mechanisms
  • M. Starr
  • Biology
    Journal of neural transmission. Parkinson's disease and dementia section
  • 1995
This review has explored the evidence and considered the practicality of using NMDA and non-NMDA receptor blockers to treat parkinsonism, as well as focusing on the ways in which the behavioural synergy between dopamine and glutamate systems could conceivably arise at the cellular level.
The antiparkinsonian agent budipine is an N-methyl-D-aspartate antagonist
It is concluded that the newly discovered NMDA antagonistic action of budipine is at least partly responsible for its antiparkinsonian activity and is additional evidence for the hypothesis that NMDA antagonists may be useful in the treatment of Parkinson's disease.
Effects of the antiparkinsonian drug budipine on neurotransmitter release in central nervous system tissue in vitro.
It is concluded that both anticholinergic and indirect dopaminomimetic properties contribute to the antiparkinsonian effects of budipine, whereas biperiden exhibits mainly antICHolinergic effects.
The antiparkinsonian drug budipine binds to NMDA and sigma receptors in postmortem human brain tissue.
The affinity of budipine to both binding sites is in a concentration range that may be reached under therapeutic conditions (Ki-values of about 12 and 2 microM at the PCP and sigma 1 binding site, respectively).
Prophylactic Treatment of Cluster Headache with Budipine